{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04535271",
            "orgStudyIdInfo": {
                "id": "SOC-2101"
            },
            "organization": {
                "fullName": "Sarcoma Oncology Research Center, LLC",
                "class": "OTHER"
            },
            "briefTitle": "Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma",
            "officialTitle": "TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Leiomyosarcoma",
            "acronym": "TAGGED",
            "therapeuticArea": [
                "Other"
            ],
            "study": "metronomic-trabectedin-gemcitabine-and-dacarbazine-for-leiomyosarcoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-09-09",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-08-27",
            "studyFirstSubmitQcDate": "2020-08-27",
            "studyFirstPostDateStruct": {
                "date": "2020-09-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-08",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sarcoma Oncology Research Center, LLC",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.",
            "detailedDescription": "This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.\n\nA total of 80 patients will receive trabectedin 0.5 mg/m2 as 24 hour continuous intravenous infusion (CIV) on D1 and D8, gemcitabine 250 mg/m2 i.v. on D1 and D8, and dacarbazine 250 mg/m2 i.v. on D1 and D8 (see product information; www.accessdata.fda.gov). Treatment cycles are given every 3 weeks. Patients in this study may continue treatment until significant disease progression or unacceptable toxicity occurs up to one year of therapy. Patients who withdraw or do not complete the first 2 treatment cycles and first follow up CT scan/MRI will be replaced."
        },
        "conditionsModule": {
            "conditions": [
                "Leiomyosarcoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Single arm",
                    "type": "EXPERIMENTAL",
                    "description": "Trabectedin 24 h CIV 0.5 mg/m2 D1 and D8 Gemcitabine i.v. 250 mg/m2 D1 and D8 Dacarbazine i.v. 250 mg/m2 D1 and D8",
                    "interventionNames": [
                        "Drug: Trabectedin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Trabectedin",
                    "description": "This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.",
                    "armGroupLabels": [
                        "Single arm"
                    ],
                    "otherNames": [
                        "Gemcitabine",
                        "Dacarbazine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression free survival",
                    "description": "Progression free survival up to disease progression or death from any cause",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Response",
                    "description": "Best overall response (BOR) and duration of response (DOR) by RECIST v1.1 via CT scan or MRI",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Adverse Event",
                    "description": "Incidence of treatment-related adverse events",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or Female \u2265 18 years of age\n* Pathologically confirmed diagnosis of locally advanced, unresectable or metastatic leiomyosarcoma\n* Previously treated patient with measurable disease by RECIST v1.1\n* ECOG performance status \u2264 2\n* Life expectancy of at least 3 months\n* Acceptable liver function: Bilirubin \\< 1.5 times upper limit of normal (ULN; except subjects with Gilbert Syndrome who must have a total bilirubin level \\< 3.0 ULN); AST (SGOT), ALT (SGPT) and alk phos \\< 2.5 x ULN (\\< 5 x ULN if liver metastases present)\n* Acceptable renal function: Creatinine \\< 1.5 times ULN and creatinine clearance \\> 60 ml/min using the Crockroft-Gault formula\n* Acceptable hematologic status: ANC \\>1000 cells/\u03bcL; Platelet count \\>100,000/\u03bcL; Hemoglobin \\> 9.0 g/dL\n* INR and PT \\< 1.5 ULN unless taking anti-coagulation, in which case PT, INR and aPTT must be within therapeutic range of intended use of anticoagulants\n* Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the Investigator's IRB/Ethics Committee\n* Willingness to comply with all study procedures and availability for the duration of the study\n* All women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours of enrollment. If urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; all subjects must agree to use highly effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 5 months for women and 7 months for men after the last dose.\n\nExclusion Criteria:\n\n* Currently receiving treatment with another investigational device or drug study, or \\<14 days since ending treatment with another investigational device or drug study(s).\n* Subject has known sensitivity to trabectedin, gemcitabine or dacarbazine.\n* Female subject is pregnant or breast-feeding or planning to become pregnant during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine.\n* Female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 3 months after the last dose of trabectedin, gemcitabine or dacarbazine.\n* Sexually active subjects and their partners unwilling to use male or female latex condom",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sant P Chawla, MD",
                    "role": "CONTACT",
                    "phone": "3105529999",
                    "email": "santchawla@sarcomaoncology.com"
                },
                {
                    "name": "Victoria Chua-Alcala, MD",
                    "role": "CONTACT",
                    "phone": "3105529999",
                    "email": "vchua@sarcomaoncology.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Sant P Chawla, MD",
                    "affiliation": "Sarcoma Oncology Research Center, LLC",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sant P Chawla",
                    "status": "RECRUITING",
                    "city": "Santa Monica",
                    "state": "California",
                    "zip": "90403",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sant P Chawla, MD",
                            "role": "CONTACT",
                            "phone": "310-552-9999",
                            "email": "santchawla@sarcomaoncology.com"
                        },
                        {
                            "name": "Victoria Chua-Alcala, MD",
                            "role": "CONTACT",
                            "phone": "3105529999",
                            "email": "vchua@sarcomaoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.01945,
                        "lon": -118.49119
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "25210398",
                    "type": "BACKGROUND",
                    "citation": "Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014 Jul;5(3):186-92. doi: 10.4103/0976-500X.136098."
                },
                {
                    "type": "BACKGROUND",
                    "citation": "www.accessdata.fda.gov/drugsatfda_docs (Trabectedin, Gemcitabine, Dacarbazine)"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007890",
                    "term": "Leiomyosarcoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009379",
                    "term": "Neoplasms, Muscle Tissue"
                },
                {
                    "id": "D000018204",
                    "term": "Neoplasms, Connective and Soft Tissue"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000012509",
                    "term": "Sarcoma"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10902",
                    "name": "Leiomyosarcoma",
                    "asFound": "Leiomyosarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20350",
                    "name": "Neoplasms, Connective and Soft Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3367",
                    "name": "Leiomyosarcoma",
                    "asFound": "Leiomyosarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000093542",
                    "term": "Gemcitabine"
                },
                {
                    "id": "D000003606",
                    "term": "Dacarbazine"
                },
                {
                    "id": "D000077606",
                    "term": "Trabectedin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2985",
                    "name": "Gemcitabine",
                    "asFound": "Mg/kg",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1862",
                    "name": "Trabectedin",
                    "asFound": "Povidone-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6809",
                    "name": "Dacarbazine",
                    "asFound": "Affect",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}